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Innate lymphoid cells (ILCs) were first described as playing important roles in the development of lymphoid
tissues and more recently in the initiation of inflammation at barrier surfaces in response to infection or
tissue damage. It has now become apparent that ILCs play more complex roles throughout the duration
of immune responses, participating in the transition from innate to adaptive immunity and contributing to
chronic inflammation. The proximity of ILCs to epithelial surfaces and their constitutive strategic positioning
in other tissues throughout the body ensures that, in spite of their rarity, ILCs are able to regulate immune
homeostasis effectively. Dysregulation of ILC function might result in chronic pathologies such as allergies,
autoimmunity, and inflammation. A new role for ILCs in the maintenance of metabolic homeostasis has
started to emerge, underlining their importance in fundamental physiological processes beyond infection
and immunity.Introduction
The innate lymphoid cell (ILC) family includes group 1 ILCs
(ILC1s) that predominantly express interferon-g (IFN-g), ILC2s
that predominantly express interleukin-5 (IL-5), IL-9, and IL-13,
and ILC3s that predominantly express IL-22 and/or IL-17 (Halim
and McKenzie, 2013; Licona-Limo´n et al., 2013; Spits et al.,
2013; Walker et al., 2013). They play roles in protective immunity
against bacteria (ILC1s and ILC3s) (Sanos et al., 2009; Sawa
et al., 2011; Sonnenberg et al., 2012), intracellular parasites
(ILC1s) (Klose et al., 2014), fungi (ILC3) (Gladiator et al., 2013),
and parasitic worms (ILC2s) (Moro et al., 2010; Neill et al.,
2010; Price et al., 2010), and in autoimmune disorders (ILC1s
and ILC3s) (Buonocore et al., 2010), allergic disease (ILC2s)
(Barlow et al., 2012), and obesity (ILC2s) (Hams et al., 2013;
Molofsky et al., 2013). Here we focus on the most recent
advances in our understanding of the role of ILCs in inflammation
and immunity, highlighting their essential roles in maintaining
immune homeostasis.
ILC2s in Type-2 Immunity
ILC2s represent a critical innate cellular source of type 2 cyto-
kines (including very high amounts of IL-5 and IL-13, but also
IL-9, IL-4, and GM-CSF) (Moro et al., 2010; Neill et al., 2010;
Price et al., 2010). The early expression of these effector cyto-
kines potently induces eosinophilia, mucus production from
goblet cells, activation of alternatively activated macrophages
(AAM), muscle contractility, mastocytosis, and contribute to
tissue repair (Allen and Sutherland, 2014; Fallon et al., 2002)
(Figure 1). The critical importance of ILC2s in type 2 immunity
has been revealed recently using gene-targeted mouse models
in which ILC2s are transferred, deleted genetically, or ablated
temporally (Liang et al., 2012; Neill et al., 2010; Oliphant et al.,
2014). ILC2s comprise the predominant source of IL-13 during
parasitic helminth infection (Moro et al., 2010; Neill et al., 2010;
Price et al., 2010) and expand in allergic lung inflammation
(Barlow et al., 2011; Chang et al., 2011; Halim et al., 2012; Klein
Wolterink et al., 2012; Mjo¨sberg et al., 2011; Monticelli et al.,
2011). Recent reports have also associated ILC2swithmetabolic366 Immunity 41, September 18, 2014 ª2014 Elsevier Inc.homeostasis, obesity, and dietary stress (Hams et al., 2013;
Molofsky et al., 2013; Stanya et al., 2013).
Control of ILC2s in the Transition from Innate to
Adaptive Immunity
Early characterization of ILC2s demonstrated that IL-2 and IL-7
potently induced their proliferation and that hematopoietic cyto-
kine gc receptor (a subunit of the IL-2, IL-4, IL-7, IL-9, IL-15, and
IL-21 receptors) signaling was critical for ILC2 development
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010). Subse-
quently, IL-4 and IL-9 have also surfaced as regulators of ILC2
activation (Motomura et al., 2014; Turner et al., 2013), and a
more complex pattern of gc-ligand control of ILC2 function has
begun to emerge. Consequently, the cellular sources and tem-
poral secretion profiles of specific ILC2-modulating cytokines
appear to evolve and fluctuate during the maturation of the
immune response. The in vivo sources of IL-7 required for ILC
development are unknown, but IL-7 is critical for the generation
andmaintenance of all lymphocytes and is expressed by stromal
cells in the bone marrow and the lymphatic endothelial cells in
lymph nodes, skin, and intestine (Hara et al., 2012). This sug-
gests that IL-7 is an early signal in ILC2 development and also
a regulator of ILC2 activity at sites where the stromal cell-derived
cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP),
which induce ILC2 growth and type 2 cytokine production, might
also be released. Basophil-derived IL-4 has also been proposed
to play a role in the ILC2 response to acute papain challenge
(Motomura et al., 2014), though a role for IL-4 was less clear in
other papain models (Halim et al., 2014). Although a number of
studies have reported little IL-4 expression by ILC2s, in vivo
antigen challenge can induce IL-4 (Oliphant et al., 2014), which
raises the possibility that it might also act as an autocrine factor.
Certainly autocrine IL-9 production by ILC2s is of importance,
being produced transiently by activated ILC2s to augment
ILC2 survival and cytokine expression (Wilhelm et al., 2011).
Indeed, the absence of IL-9 results in reduced ILC2-derived
amphiregulin expression and impaired tissue repair (Turner
et al., 2013).
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Figure 1. ILC2s in Type 2 Immunity and
Homeostasis
Stimuli such as allergens or parasitic worms lead
to the release of ILC2-inducing factors from
the epithelium and infiltrating inflammatory cells.
These cytokines cause ILC2s to proliferate and
produce type 2 cytokines and activate type 2
effector pathways. This leads to the transition from
innate to adaptive immunity. ILC2s also contribute
to maintaining metabolic homeostasis. PGD2,
prostaglandin D2 receptor; LTD4, leukotriene D4.
See main text for details on differences between
human and mouse.
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been proposed recently (Drake et al., 2014; Mirchandani et al.,
2014; Oliphant et al., 2014). Through their expression of major
histocompatibility complex II (MHCII), ILC2s can present antigen
to T cells, though less efficiently than dendritic cells (DCs),
inducing T cell-derived IL-2 production. Consequently, ILC2s,
which express IL-2 receptors, proliferate and generate a highly
enriched type 2 cytokine environment. This crosstalk between
ILC2s and T cells is functionally important, because, in contrast
to wild-type ILC2s, transfer of MHCII-deficient ILC2s into Il13/
mice resulted in a delay in expulsion of parasitic helminth worms
(Oliphant et al., 2014). IL-4 and OX40 ligand (OX40L) have also
been suggested to contribute to the stimulatory crosstalk be-
tween ILC2s and T cells (Drake et al., 2014). Such T cell- and
ILC2-derived signals appear to be important for maintaining
ILC2s at the site of inflammation (Neill et al., 2010) and suggest
that as the immune response matures ILC2s move from stromal
and autocrine cytokine dependence to cytokines produced by
the adaptive response. In addition to this dialog between ILC2s
and T cells, ILC2s can also influence the onset of the adaptive
T helper 2 (Th2) cell-mediated response by modifying DC func-
tion. ILC2-derived IL-13 was critical for rapid induction of Th2
cells, not by acting directly on naive CD4+ T cells, but by
licensing the migration of activated DCs to the lung-draining
lymph node (Halim et al., 2014). Therefore it was suggested
that the deficit in primed DCs in the secondary lymphoid organs,
in the absence of ILC2-produced IL-13, led to impaired Th2 cell
priming (Halim et al., 2014). The involvement of ILC2s in theImmunity 41, Sematuration of adaptive type 2 immunity
appears to be limited to local mucosal
surfaces since systemic antigen exposure
was not perturbed by the absence of
ILC2s (Gold et al., 2014). It waits to be
determined whether ILC2 might also
indulge in an antagonistic discourse with
T cells leading to dampened responses
such as those reported for ILC3 interac-
tions with T cells (Hepworth et al., 2013).
Importantly, and perhaps consistent
with an enduring dialog with the adaptive
immune system, ILC2s are associated
with chronic human diseases, such as
asthma, cirrhosis, idiopathic pulmonary
fibrosis, and atopic dermatitis, where
they correlate with IL-25, IL-33, and/or
TSLP cytokine profiles. Experimentalmouse models have confirmed the functional involvement of
ILC2s in these diseases; for example, IL-25 was sufficient to
induce IL-13-secreting ILC2s and the onset of collagen deposi-
tion in the lungs of mice challenged with type 2 response-
inducing schistosome eggs (Hams et al., 2014). Similarly,
IL-33-deficient mice and ILC2 depletion strategies were used
to demonstrate that IL-33-induced ILC2s were required for tis-
sue remodeling and fibrosis in a mouse model of hepatic fibrosis
(McHedlidze et al., 2013). However, the IL-33-ILC2-IL-13 axis
has also been reported to mediate tissue repair functions in a
mouse model of biliary injury by promoting epithelial restoration
(Li et al., 2014). Similarly, lung ILC2s expressed amphiregulin to
regulate wound healing after infection with the H1N1 influenza
virus, where they initially exacerbate viral-induced airway hyper-
sensitivity (Monticelli et al., 2011). Together these data illustrate
that ILC2s, depending on the disease and experimental model,
can contribute both to pathology and tissue repair.
ILC2s in Allergy and Asthma
Consistent with the identification of a gene signature (IL1LR1 [IL-
33R], RORA, IL2RB, and IL13) in human asthma that implicates
ILC2 involvement (Moffatt et al., 2010), ILC2s have been shown
to expand in experimental models of allergic lung inflammation in
mice, and their production of type 2 cytokines contributes to dis-
ease pathology (Barlow et al., 2011; Chang et al., 2011; Halim
et al., 2012; Klein Wolterink et al., 2012; Mjo¨sberg et al., 2011;
Monticelli et al., 2011). Induction of ILC2s during the early phase
ofmucosal immune responses is achieved through the actions of
the epithelium-derived cytokines IL-25, IL-33, and TSLP, whichptember 18, 2014 ª2014 Elsevier Inc. 367
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ing and viral asthma exacerbation (Gorski et al., 2013; Gregory
et al., 2013; Hong et al., 2014; Saglani et al., 2013). These cyto-
kines show redundancy in the induction of ILC2s to various stim-
uli (Neill et al., 2010; Salimi et al., 2013; Van Dyken et al., 2014)
and are now joined by TL1A (Tnfsf15), a tumor necrosis factor
(TNF)-family member that can also directly activate ILC2s to pro-
duce type 2 cytokines (Meylan et al., 2013; Yu et al., 2013).
Although these cytokines display a degree of redundancy, the
signaling pathways for these molecules are discrete and func-
tional differences have been reported. For example, IL-33 has
been shown to have a more potent effect on ILC2 activity than
IL-25 in response to ragweed and Alternaria alternata challenge
(Barlow et al., 2013; Hardman et al., 2013). Furthermore, induced
steroid resistance of ILC2s was recently reported as TSLP
dependent (Kabata et al., 2013), where IL-33 in combination
with antigen resulted in ILC2s with increased resistance to ste-
roid treatment than T cells. This required STAT5 and could be
inhibited with pimozide (a STAT5-inhibiting antipsychotic drug).
Atopic dermatitis (AD) is a common pruritic inflammatory skin
disease associated with barrier dysfunction and adaptive im-
mune responses to common environmental allergens, charac-
terized by the presence of Th2 cells and high amounts of IL-13
and IL-4 and often associated with asthma (Kim et al., 2012;
Leung et al., 2004). Increased transcripts encoding IL-33 and
IL-25 have been detected in acute lesional atopic dermatitis
skin (Hvid et al., 2011; Miller, 2011), and ILC2s have been re-
ported recently to arise with increased frequency in mouse and
human atopic lesional skin (Kim et al., 2012; Salimi et al., 2013).
Notably, Ogg and colleagues proposed a mechanism for ILC2
sensing of barrier dysfunction in humans through the inhibitory
receptor KLRG1. They demonstrated in vitro that the presence
of E-cadherin, a known ligand of KLRG1, downregulated ILC2
cytokine expression (Salimi et al., 2013). As E-cadherin expres-
sion is reduced in AD lesions, this pathway might contribute to
cytokine hyperproduction by skin ILC2s. A calcipotriol-induced
mouse model of atopic dermatitis-like inflammation supported
a role for ILC2s, independently of T cells, in the initiation of
skin inflammation and the involvement of IL-25, IL-33, or TSLP
in ILC2 induction in the skin (Kim et al., 2013; Salimi et al.,
2013). Thus, ILC2s are regulated by a spectrum of epithelium-
derived factors that influence their threshold of activation in
response to infection or tissue damage.
Inhibiting ILC2s
In addition to biologics, such as antibodies against IL-25, IL-33,
and TSLP that might be used to inhibit ILC2 proliferation and
function (Ballantyne et al., 2007; Coyle et al., 1999; Gauvreau
et al., 2014; He et al., 2008), a number of small molecule inhibi-
tors have been shown to block ILC2 function by inhibiting arach-
adonic acid metabolites. For example, blocking prostaglandin
D2 (PGD2) binding to chemoattractant receptor-homologous
molecule expressed on Th2 cells (CRTH2), which is highly ex-
pressed on human ILC2s, inhibits ILC2 chemoattraction and
expression of IL-4, IL-5, IL-9, and IL-13 (Barnig et al., 2013;
Chang et al., 2013; Xue et al., 2014). As mast cells produce
PGD2 predominantly after immunoglobulin E (IgE)-high-affinity
IgE receptor (FcεRI) crosslinking, ILC2s might be attracted and
activated by this pathway during adaptive type 2 immune re-
sponses. Notably, intravital imaging of mouse skin indicated368 Immunity 41, September 18, 2014 ª2014 Elsevier Inc.that ILC2s interact with mast cells and produced IL-13 (Roediger
et al., 2013). Similarly ILC2s express cysteinyl leukotriene
receptor 1 (CysLT1R) and respond to leukotriene D4 (LTD4) by
expressing type 2 cytokines, which can be inhibited by Montelu-
kast, a leukotriene receptor antagonist (Doherty et al., 2013; Xue
et al., 2014). Human ILC2s also bind the resolvin, lipoxin A4, an
anti-inflammatory derivative of arachadonic acid that partially
inhibited ILC2-produced IL-13 in vitro (Barnig et al., 2013).
Thus, to-date potential therapeutic strategies have focused on
targeting solublemediators that activate ILC2s. In future, a better
understanding of the factors required for ILC2 development
and maintenance might facilitate more specific approaches to
directly target ILC2s.
ILC2s in Diet and Obesity
Growing evidence links ILC2s and type 2 cytokines with meta-
bolic homeostasis, obesity, and dietary stress (Hams et al.,
2013; Molofsky et al., 2013; Stanya et al., 2013). ILC2s are widely
distributed in tissues of the body and are found constitutively in
visceral adipose tissue (VAT). Here they provide IL-5 and IL-13
for the maintenance and induction of eosinophils and AAM,
with deficiency of IL-5 and IL-13 leading to increased adiposity
and insulin resistance (Molofsky et al., 2013). ILC2s have also
been reported recently to coexpress IL-5 and IL-13 during the
daily cycle of caloric intake and respond to the circadian syn-
chronizer, vasoactive intestinal peptide via the VPAC2 receptor,
resulting in cytokine expression associating with daily circadian
rhythms (Nussbaum et al., 2013). Notably, administration of both
IL-25 and IL-33 increased ILC2 cell numbers in mice fed a high-
fat diet (HFD) and maintained a lean phenotype (Hams et al.,
2013). However, the mechanisms by which eosinophils and
AAM regulate glucose homeostasis and weight gain remain to
be fully elucidated.
Just as overindulgence can destabilize the balance of ILC2-
mediated cytokine regulation of metabolic homeostasis, so
malnutrition can also disrupt ILC-regulated immunity. Vitamin A
deficiency has been associated with immunodeficiency (Hall
et al., 2011). Indeed, dietary deprivation of vitamin A in mice re-
sulted in reduced frequencies of intestinal ILC3s, and this led to
increased susceptibility to gastrointestinal bacterial infection
withCitrobacter rodentium (Spencer et al., 2014). By contrast, in-
testinal ILC2s actually increased in frequency following vitamin A
restriction and the mice displayed enhanced resistance to para-
sitic helminth infection. Administration of retinoic acid (a metab-
olite of vitamin A) to Rag2/mice induced ILC3, while a retinoic
acid inhibitor stimulated ILC2 accumulation, probably through
effects on retinoic acid sensitive ILC precursors. Thus, micronu-
trient deficiency might selectively provoke specific immune
pathways that promote survival during periods of malnutrition.
The authors suggest that although a deficiency in ILC3s might
expose the host to acute intestinal pathogens, an increase in
ILC2s might lessen the impact from commensals and helminth
parasites when nutrients are limiting.
Thus ILC2s appear to be critically positioned to respond to
environmental cues including metabolic stress and nutrient
intake to maintain homeostasis and poised to rapidly respond
to damage in multiple tissues. Upon epithelial damage, ILC2s
become activated and provide immune stimulatory and wound
healing signals. If injury continues, they might contribute to
chronic pathology such as fibrosis and potentiate adaptive
Figure 2. ILC1s and ILC3s in Immunity and
Homeostasis
ILC3s maintain homeostasis in the presence of
intestinal symbionts, but respond by inducing
epithelial cell release of defensins such as RegIII
upon mucosal invasion. ILC3s in the spleen induce
antibody production. LTi initiate lymphoid tissue
development. LT, lymphotoxin; ieILC1, intestinal
epithelium ILC1; DC, dendritic cell; TCR, T cell
receptor, DLL1, delta-like ligand 1; LTi, lymphoid
tissue inducer. See main text for details on differ-
ences between human and mouse.
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immune responses, other members of the ILC family have been
shown to be central in type 1 and Th17 cell-mediated immunity
and disease.
ILC3s in Homeostasis and Immunity
Group 3 ILCs are defined by their expression of RORgt and
include lymphoid tissue inducer (LTi) cells (the first ILC3 subset
that was discovered in the late 1990’s; Adachi et al., 1997;
Mebius et al., 1997) and ILC3s that express natural cytotoxicity
triggering receptors (NCRs) and predominantly secrete IL-22
(Spits et al., 2013; Walker et al., 2013) (Figure 2). ILC3s express
cytokines that play a central role in the development of
lymphoid tissues and in the equilibrium between host and
microbes at mucosal surfaces (Philip and Artis, 2013). Expres-
sion of membrane lymphotoxin (LT) a1b2 by LTi cells, expressing
chemokine receptor 6 (CCR6) (Adachi et al., 1997; Mebius et al.,
1997), is required in the fetus to induce the development of
lymph nodes and Peyer’s patches through LTb receptor
(LTbR) expressed on stromal cells (De Togni et al., 1994; Eberl
et al., 2004). After birth, a similar pathway leads to the formation
of isolated lymphoid follicles (ILFs) in the intestinal lamina prop-
ria (Bouskra et al., 2008). Through LTa1b2, ILC3s also activate
intestinal epithelial cells to produce the chemokines chemokine
(C-X-C motif) ligand 1 (CXCL1) and CXCL2 in response to infec-
tion by Citrobacter rodentium (Wang et al., 2010). These chemo-
kines are associated with neutrophil recruitment and improved
bacterial clearance.
The LTa1b2 pathway is further involved in the positive regula-
tion of IL-22, a cytokine produced by ILC3s, which plays a
fundamental role in mucosal immunity through its effects on
epithelial cells. Both LTi cells and the other major subset of
CCR6 NKp46+ ILC3s are the major producers of IL-22 (Cella
et al., 2009; Cupedo et al., 2009; Satoh-Takayama et al.,
2008), because mice lacking ILC3s largely recapitulate the
phenotype of IL-22-deficient mice (Zheng et al., 2008). IL-22-
production by ILC3s is induced by IL-23 produced by DCs in a
STAT3-dependent manner, whereas ILC3s enhance IL-23 pro-
duction by DCs through activation of LTbR in a positive feedback
loop (Tumanov et al., 2011). Upon activation by IL-22, epithelial
cells express antimicrobial proteins (AMPs) such as RegIIIb
and RegIIIg, which establish a gradient of resistance to bacterial
colonization in the intestinal lumen (Liang et al., 2006). InImmunity 41, Sethe absence of IL-22, susceptibility to
C. rodentium infection (Zheng et al.,
2008) and dextran sodium sulfate (DSS)-
induced colitis (Zenewicz et al., 2008) isincreased, and containment of invasive symbionts is significantly
decreased (Sonnenberg et al., 2012).
ILC3s in Disease
In contrast to their protective role in producing IL-22, ILC3s can
also promote pathology. IL-22 can contribute to colon cancer in
susceptible 129SvEv.Rag/ mice infected with Helicobacter
hepaticus and treated with the genotoxin 2-azoxymethane
(AOM) (Kirchberger et al., 2013). Thus, IL-22 is a double-edged
sword, induced to protect from intestinal damage, but promoting
tumorigenesis when uncontrolled (Huber et al., 2012). Thus, IL-
22 activity must be tightly controlled, at least in part, by the
DC-produced IL-22-binding protein that neutralizes IL-22 (Huber
et al., 2012). Interestingly, IL-22-producing CD3 cells were
found within human colorectal carcinoma (CRC) tumors, and
these cells might constitute ILC3s. However, a role for IL-22 in
human carcinogenesis has yet to be determined (Kirchberger
et al., 2013).
The frequencies of ILC3s are significantly increased in skin
lesions and also in peripheral blood of psoriasis patients (Teunis-
sen et al., 2014; Villanova et al., 2014). Interestingly, one patient
who showed a therapeutic response to anti-TNF antibodies, as
evidenced by reduction in psoriatic plaques, had an associated
decrease in circulating NCR+ILC3 (Villanova et al., 2014). IL-17-
and IL-22-producing NCR+ILC3s were also induced in skin
lesions of mice that develop a psoriasis-like disease following
treatment with Aldara cream, and loss of IL-17 and IL-22
reduced the severity of the disease (Pantelyushin et al., 2012).
These findings together suggest a role of NCR+ILC3 in psoriasis.
IL-17-production by ILC3s has now also been linked with
obesity-associated asthma, through a mechanism that involves
the induction of IL-1b expression by macrophages after feeding
mice a high-fat diet (Kim et al., 2014). Notably, IL-22 produced by
ILC3s favors the development of obesity, although this occurs
indirectly by controlling the composition of the intestinal micro-
biota (Upadhyay et al., 2012). Because the ratio of type 2 to
type 1 cytokines appears to play a key role in regulating obesity,
it will be informative to determine whether IFN-g-expressing
ILC1s (or ‘‘ex-ILC3s’’) influence weight gain by skewing macro-
phage polarization to an M1-phenotype.
A correlation between ILC3s and multiple sclerosis (MS) has
also been reported recently (Perry et al., 2012). An increased fre-
quency of ILC3s was shown to associate with MS and treatmentptember 18, 2014 ª2014 Elsevier Inc. 369
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the reduction of ILC3s in peripheral blood and a decrease in
intrathecal inflammation. However, the effects of anti-CD25
treatment extend beyond ILC3s, and an initial report using a
mouse model of experimental autoimmune encephalomyelitis
(EAE) failed to show a causative role for ILC3s in this disease
(Mair and Becher, 2014).
ILC3s Crosstalk with Adaptive T and B Cells
New functions for ILC3s in influencing adaptive immunity have
recently been discovered. In Th17 cells, the production of GM-
CSF has been associated with autoimmune inflammation in the
models of EAE and collagen-induced arthritis (CIA) (Codarri
et al., 2011; El-Behi et al., 2011). However, during intestinal
homeostasis, another role for GM-CSF has been uncovered.
Microbiota activate the production of IL-1b by macrophages,
which induces GM-CSF production by ILC3s. GM-CSF then
feeds back on macrophages to produce retinoic acid (RA) and
induce the differentiation of regulatory T (Treg) cells, thereby pro-
moting oral tolerance (Mortha et al., 2014). Earlier, it was shown
that RA promotes the generation of Tregs that express RORgt,
the signature transcription factor for ILC3s and Th17 cells (Loch-
ner et al., 2008). An association between RA and ILC3-mediated
responses has been further documented during the fetal matura-
tion of LTi cells through RA receptors (RAR) or retinoid X recep-
tors (RXR) binding to RA response elements in the Rorgt locus
(van de Pavert et al., 2014), and the lineage decision between
ILC2s and ILC3s (Spencer et al., 2014).
Even though ILC3s were known to express MHCII (Eberl et al.,
2004;Mebius et al., 1997), only recently have they been shown to
produce the antigen-processing machinery for class II presenta-
tion and be able to regulate T cell responses to microbiota (Hep-
worth et al., 2013). Whether antigen presentation by ILC3s can
also induce T cell effectors in an inflammatory context remains
to be assessed. In return, lymphocytes negatively regulate the
number and function of ILCs. In RAG-deficient mice, the expres-
sion of IL-22 by ILC3s is increased (Korn et al., 2014; Sawa et al.,
2011). However, it is unclear whether this results from the direct
inhibition of ILC3s by T or B cells or whether it is due to
decreased competition for a common stimulating factor, such
as IL-23. In addition, DCs have been found to negatively regulate
the activity of ILC3s during homeostasis by relaying type 2 sig-
nals such as IL-25, induced by microbiota and produced by
epithelial cells (Sawa et al., 2011).
Gut ILC3s also interact with B cells. They promote the produc-
tion of IgA through both membrane LTa1b2 and soluble LTa3, the
former regulating DC activity through LTbR, and the latter pro-
moting the recruitment of T cells through TNF receptors (Kruglov
et al., 2013). In both mice and humans, ILC3s are located in the
perifollicular zone of the spleen, where they communicate with
marginal reticular cells via TNF and LTa1b2 (Magri et al., 2014).
Human splenic ILC3s express the plasma cell survival factor B
cell activating factor (BAFF), CD40 ligand (CD40L), and Delta-
like ligand (DLL) 1, which collaborate to activate marginal zone
B cells to produce IgM (Magri et al., 2014). Human ILC3 co-opt
neutrophils, probably through IL-8, that have marginal zone
(MZ) plasma cell helper function to sustain T cell-independent
antibody production. In mice, splenic ILC3s do not express
BAFF or CD40L but do express DLL1 and the BAFF-related
molecule a proliferation-inducing ligand (APRIL) and enhance370 Immunity 41, September 18, 2014 ª2014 Elsevier Inc.IgG3, rather than IgM production. Mice do not express IL-8
and in their spleen neutrophils are recruited through GM-CSF
(Magri et al., 2014). Thus in both mice and humans ILC3s aid
T cell-independent antibody production, but through different
mechanisms. Thus, in addition to providing innate regulation of
intestinal homeostasis, ILC3s can influence T andB cells through
a variety of mechanisms to either suppress or activate adaptive
immunity.
ILC1 in Immunity and Pathology
NKCells and ILC1s. Recent studies have providedmore insight
in the relationship of NK cells and other IFN-g-producing ILCs.
Initially, conventional (c) NK cells were classified in group 1
ILCs because they produce vast amounts of IFN-g and express
the transcription factor T-bet. However, cNK cells turn out to
differ from other group 1 ILC subsets because they are develop-
mentally dependent on Eomesodermin (Eomes, a T box tran-
scription factor related to T-bet) and not on T-bet. Moreover, in
contrast to other ILC1 subsets, NK cells express molecules,
such as perforin, that mediate cytotoxic activity. Based on this
and on studies into the developmental pathway of cNK cells
and ILCs, it has been proposed that ILC1s, ILC2s, and ILC3s
are the innate counterparts of CD4+ T helper cells, whereas NK
cells are the innate equivalents of CD8+ cytotoxic T cells (Fuchs
et al., 2013; Klose et al., 2014).
A T-bet-dependent Eomes-independent ILC1 subset was
recently identified by RORgt cell-fate mapping in combination
with a reporter allele for the transcription factor Eomes; these
cells expressed NK1.1 and T-bet, but not Eomes, and were
negative by RORgt lineage fate mapping. Like cNK cells, the
NK1.1+ILC1s are dependent on IL-15, although they do express
the IL-7Ra chain (CD127). The NK1.1+ ILC1s also expressed
CD27 and produced high amounts of IFN-g and TNF and pro-
tected mice against infection with the protozoan intracellular
parasite Toxoplasma gondii (Klose et al., 2014).
Plasticity of ILC1s and ILC3s. A Tbet+EomesCD127+ ILC1
subset, which is RORgt-dependent, was found in the mouse
gut (Vonarbourg et al., 2010). A similar ILC1 subset was identified
in lymphoid organs, tissues, and peripheral blood of humans
(Bernink et al., 2013). In both humans and mice, these cells
may arise from ILC3s downregulating RORgt and upregulating
T-bet under the influence of inflammatory stimuli such as IL-
12, IL-18, and IL-15 (Bernink et al., 2013; Vonarbourg et al.,
2010). The ILC3-derived ILC1s (which are also referred to in
some studies as ex-ILC3s) are therefore distinct from the
NK1.1+RORgt fate-map-negative ILC1s that never expressed
RORgt during their development (Klose et al., 2014). In the
mouse, development of ILC3s into ILC1s occurs gradually.
NKp46ILC3s acquire the capacity to produce IFN-g when
they develop into NKp46+ ILC3s in a T-bet-dependent way.
Expression of T-bet results in a lower expression of RORgt and
the ratio of RORgt and T-bet can be decreased further under
the influence of cytokines such as IL-12 and IL-18, resulting in
loss of the capacity to produce IL-17 and IL-22. Thus a gradient
of RORgt and T-bet determines the phenotype and cytokine pro-
duction of ILC3s and ILC3-derived ILC1s (Klose et al., 2013).
A similar differentiation of ILC3s into ILC1s was observed in
humans but the transition of IL-22+ and/or IL-17+ ILC3s into
IFN-g-producing ILC1s was clearly distinguished by their down-
regulation of c-Kit and NKp44 expression (Bernink et al., 2013).
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ReviewThe c-Kit+NKp44+ ILC3s expressed RORgt, but no T-bet,
whereas the ILC1s that developed from these cells lacked
NKp44 and c-Kit, and expressed T-bet, but minimal amounts
of RORgt (Bernink et al., 2013). ILC3s that adopt characteristics
of ILC1s or differentiate into ILC1s (producing IFN-g variably with
IL-17 and/or IL-22) have been reported in the context of colitis in
mouse and human and associated with intestinal pathology
(Bernink et al., 2013; Buonocore et al., 2010; Coccia et al.,
2012; Ermann et al., 2014; Geremia et al., 2011). Similar
functions are expressed by CCR6 ILC3s during infection by
Salmonella enterica, which also drive enterocolitis through
T-bet-controlled production of IFN-g as a result of the infection
(Klose et al., 2013).
Another member of group 1 ILCs was described to be present
specifically in the intestinal epithelium (ie) in both mice and hu-
mans and are termed ieILC1s (Fuchs et al., 2013). In humans,
these cells expressed the NK marker CD94 and perforin, sug-
gesting that they are closely related to cNK cells, but the mouse
equivalent of these cells appears to develop in an IL-15-indepen-
dent manner (Fuchs et al., 2013). Like ILC3-derived ILC1s,
ieILC1s are also expanded in the intestine of Crohn’s disease
patients (Bernink et al., 2013, Fuchs et al., 2013), and in mice
these ILC1 subsets promote colitis, presumably through their
production of IFN-g (Fuchs et al., 2013; Vonarbourg et al., 2010).
Perspectives
Recent work has led to a better understanding of the diversity of
ILC subsets and their plasticity. Whereas ILCs were originally
associated with acute innate immune responses to infection
and tissue remodeling, it is now clear that ILCs play a much
broader role as they are also involved in the regulation of adap-
tive immunity, chronic inflammation, and metabolic homeosta-
sis. Although ILCs are present in small numbers in tissues, their
strategic location at mucosal barriers in intimate proximity with
epithelial surfaces enables them to regulate maintenance of
immune homeostasis by balancing destructive immunity and
‘‘constructive’’ repair responses. It is clear that excessive activa-
tionmay lead to ILCs contributing to chronic pathologies such as
allergies, autoimmunity and inflammation, and the activation of
adaptive immunity. Future research should be directed at under-
standing the mechanisms underlying the extensive array of bio-
logical activities of ILCs, especially in disease, and open new
preventive and therapeutic avenues based on the modulation
of ILC activity.
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